Relationship of Cholelithiasis and Urolithiasis with Methylenetetrahydrofolate Reductase Polymorphisms.


Journal

Journal of investigative surgery : the official journal of the Academy of Surgical Research
ISSN: 1521-0553
Titre abrégé: J Invest Surg
Pays: United States
ID NLM: 8809255

Informations de publication

Date de publication:
Oct 2021
Historique:
pubmed: 2 4 2020
medline: 3 11 2021
entrez: 2 4 2020
Statut: ppublish

Résumé

To investigate the relationship of cholelithiasis and urolithiasis with This study is consisted of 94 patients with poor obstetric history. Patients were evaluated in terms of the presence of cholelithiasis and urolithiasis in association with MTHFR polymorphism(s). Additional laboratory tests including homocysteine measurements were also performed. ROC analysis for assessing the performance of blood homocysteine level in predicting the presence of cholelithiasis and urolithiasis were also performed. Patients were divided into three groups such as cholelithiasis group (n = 9, 9.6%), urolithiasis group (n = 18, 19.1%) and control group (n = 67, 71.3%). Groups did not differ in term of age and Beksac obstetrics index (BOI) which is "[living child+(π/10)]/gravidity." The rate of the presence of MTHFR polymorphisms were 88.9% (8/9), 88.9% (16/18) and 43.3% (29/67) in cholelithiasis, urolithiasis and control groups respectively. Median homocysteine levels were found to be 13.1, 11.6 and 7.2 micromol/lt for the groups respectively. Statistically significant differences were found for MTHFR polymorphism rates and homocysteine levels (<0.001 for both). According to ROC analysis, 10.9 mcmol/L (88.9% sensitivity, 89.6% specificity) and 9.25 mcmol/L (83.3% sensitivity, 73.1% specificity) were determined to be cutoff values of homocysteine for cholelithiasis and urolithiasis respectively. More frequent MTHFR polymorphisms are observed in women with a clinical history of gall or renal stones. Thus, screening of these patients may be benefical for the approprate management of their subsequent pregnancies.

Identifiants

pubmed: 32228104
doi: 10.1080/08941939.2020.1742402
doi:

Substances chimiques

Methylenetetrahydrofolate Reductase (NADPH2) EC 1.5.1.20

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1104-1107

Commentaires et corrections

Type : CommentIn

Auteurs

Kemal Beksac (K)

Department of General Surgery, Ankara Oncology Hospital, Ankara, Turkey.

Atakan Tanacan (A)

Division of Perinatology, Hacettepe University, Ankara, Turkey.

Murat Cagan (M)

Division of Perinatology, Hacettepe University, Ankara, Turkey.

Hanife Güler Dönmez (HG)

Department of Biology, Hacettepe University, Ankara, Turkey.

Erdem Fadiloglu (E)

Division of Perinatology, Hacettepe University, Ankara, Turkey.

Canan Unal (C)

Division of Perinatology, Hacettepe University, Ankara, Turkey.

M S Beksac (MS)

Division of Perinatology, Hacettepe University, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH